About
TreatResp will evaluate the clinical effectiveness and cost-effectiveness of therapeutics for respiratory pathogens in non-hospitalized patients and build off lessons learned from prior Canadian trials, such as CanTreatCOVID.
Adaptive platform trials (APTs) like TreatResp and CanTreatCOVID are designed to compare multiple therapies in an efficient manner and allow us to respond to the dynamic nature of pandemics. Therapeutics to be evaluated will be identified through a transparent TreatResp Therapeutics Committee.
TreatResp will use numerous approaches to recruit participants from diverse populations to the study, including through links to primary care clinics and emergency departments engaged in the PREPARED research study.
Impact
Our findings will:
1) Establish an adaptive platform trial aimed at evaluating comparative clinical effectiveness and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens for non-hospitalized patients.
2) Generate evidence relevant to communities made vulnerable by social and economic policies, particularly those historically excluded from research.
3) Provide rapid evidence to inform clinical and health system management and public health leaders, decision-makers, and planners internationally.